Thermo Fisher Scientific CD134 (OX40) Monoclonal Antibody (OX-86), Super Bright 780, eBioscience

Applications

Tested Dilution

Publications

Flow Cytometry (Flow)

1.0 µg/test

View 2 publications 2 publications

Product Specifications

Published species

Not Applicable

Host/Isotype

Rat / IgG1, kappa

Recommended Isotype Control

Rat IgG1 kappa Isotype Control (eBRG1), Super Bright™ 780, eBioscience™

Class

Monoclonal

Type

Antibody

Clone

OX-86

Conjugate

Super Bright™ 780 Super Bright™ 780 Super Bright™ 780

View additional formats

• Unconjugated
• APC
• Functional Grade
• PE
• PE-Cyanine7
• PerCP-eFluor 710
• Super Bright 436
• Request custom conjugation

Excitation/Emission Max

413/780 nm View spectra

Form

Liquid

Concentration

0.2 mg/mL

Storage conditions

4° C, store in dark, DO NOT FREEZE!

Shipping conditions

Wet ice

RRID

AB_2734875

Product Specific Information

Description: The OX-86 monoclonal antibody reacts with mouse CD134, also known as OX40. A member of the TNF receptor superfamily, CD134 is a 50 kDa type I membrane glycoprotein expressed by activated mouse T lymphocytes. Rat CD134 was initially identified as an activation marker only on activated CD4+ T cells. In contrast, mouse CD134 is expressed by both activated CD4+ and CD8+ T cells. The interaction of CD134 with CD252 (OX40 ligand) has been implicated in T cell-dependent humoral responses, regulation of primary T cell expansion, survival of T cells, size of the memory T cell pool, and regulation of tolerance in the CD4+ T cell compartment.

Applications Reported: The OX-86 antibody has been reported for use in flow cytometric analysis.

Applications Tested: The OX-86 antibody has been tested by flow cytometric analysis of activated mouse splenocytes. This can be used at less than or equal to 1.0 µg per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest.

Super Bright 780 is a tandem dye that can be excited with the violet laser line (405 nm) and emits at 780 nm. We recommend using a 780/60 bandpass filter. Please make sure that your instrument is capable of detecting this fluorochrome.

When using two or more Super Bright dye-conjugated antibodies in a staining panel, it is recommended to use Super Bright Complete Staining Buffer (Product # SB-4401) to minimize any non-specific polymer interactions. Please refer to the datasheet for Super Bright Staining Buffer for more information.

In some experiments, we have observed that compensation values for Super Bright 780-conjugated antibodies are higher in the violet 450/50 channel when using UltraComp eBeads microspheres (Product # 01-2222-42) as compared to single-color stained cells. In such circumstances, we would recommend setting compensation with cells. We have also observed this in some experiments using AbC Total Antibody Compensation beads (Product # A10497).

Light sensitivity: This tandem dye is sensitive to photo-induced oxidation. Please protect this vial and stained samples from light.

Fixation: Samples can be stored in IC Fixation Buffer (Product # 00-8222) (100 µL of cell sample + 100 µL of IC Fixation Buffer) or 1-step Fix/Lyse Solution (Product # 00-5333) for up to 3 days in the dark at 4°C with minimal impact on brightness and FRET efficiency/compensation. Some generalizations regarding fluorophore performance after fixation can be made, but clone specific performance should be determined empirically.

Excitation: 405 nm; Emission: 780 nm; Laser: Violet Laser.

Super Bright Polymer Dyes are sold under license from Becton, Dickinson and Company.

Target Information

OX40 is a protein receptor found on the surface of T cells, a type of white blood cell that plays a crucial role in the immune system. When activated, OX40 promotes the proliferation and survival of T cells, leading to a stronger immune response against cancer cells and infectious agents. OX40 agonists, which are drugs that activate OX40, have shown promising results in preclinical and clinical studies as a potential immunotherapy for cancer. They can enhance the efficacy of other cancer treatments such as chemotherapy and checkpoint inhibitors, and may also have applications in autoimmune diseases and allergies.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.